Pyramid Analytics Expands UK Presence With Launch of Public Sector Practice
15.9.2022 04:46:00 EEST | Business Wire | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today announced the launch of a UK Public Sector Practice. The new division will bring the transformational power of augmented analytics to public departments, agencies and public bodies across the United Kingdom. Decision Intelligence enabled by AI and machine learning can modernize the delivery of critical public services, including healthcare, utilities, and transportation in Europe’s largest public sector market. There are 23 ministerial departments, 20 non-ministerial departments, 417 agencies and other public bodies, and 14 public corporations in the UK1.
Key Points:
- The Guardian reported that UK government spending on technology R&D is estimated to reach £14.9 billion for 2021 and 2022, and the government aims to increase this to £22 billion by 2026–27.
- The UK Public Sector practice will be led by Alastair Roriston, an experienced leader of successful programmes to connect technology with the needs of government agencies.
- Pyramid has a long track record of enabling technology innovation in the public sector. Government customers include the United States Department of Veterans Affairs, Israel Aerospace Industries, Israel Defense Forces, Ministry of Defence of the Republic of Slovenia, and Statistics Finland.
- The Pyramid Decision Intelligence Platform, training and services will be provided directly and through partnerships.
- Decision Intelligence will help frontline public sector workers to make faster and more informed decisions, elevating the level of service for the general public.
A New Future for the UK Public Sector
The COVID-19 pandemic accelerated digital transformation across all sectors of the economy and society, and government needs to keep pace. Spearheaded with a clear mandate from Cabinet Office, the UK government is leading the way in reimagining how data can be used to improve the operations of the public sector and the standard of service they offer to ordinary people every day.
NHS England unveiled plans in April to develop a federated data platform (FDP), with an estimated procurement value of £240 million. According to the notice, the FDP will be “an ecosystem of technologies and services” and “an essential enabler to transformational improvements across the NHS”. It will be built around five major use cases: population health and person insight, care co-ordination, elective recovery, vaccines and immunisation, and the supply chain.
Pyramid Experience with Massive Public Healthcare Systems
The Pyramid Decision Intelligence Platform is currently used by the United States Department of Veteran Affairs (VA), a Cabinet-level executive branch department of the federal government charged with providing life-long healthcare services to eligible military veterans at the 170 medical centers and outpatient clinics located throughout the country. The VA provides comprehensive healthcare services to 9 million veterans.
The Pyramid Decision Intelligence Platform is used by clinical, medical and administrative staff to identify patterns and execution gaps across the system, ensuring US military veterans receive more personalised and enhanced care. So far, a programme run by just three people has trained 40,000 staff in the use of the platform, with plans to eventually equip 60,000 to start using Decision Intelligence to improve the services they offer to US military veterans and their families.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Tom Warren , Regional Managing Director, UKI, Pyramid Analytics:
“The Pyramid family are excited to announce this next chapter of our story. We look forward to enabling the digital transformation of UK public sector organisations, helping to deliver better, faster and more efficient services to those who need them the most. We hope to use Decision Intelligence to turn data analytics in the public sector from the complex to the simple with decision intelligence.
“I am excited to be working with the highly experienced and forward-thinking Alastair Roriston to advance Pyramid’s expansion into the UK public sector. He joins an already successful and high-performing team, who have been instrumental to Pyramid’s expansion in the UKI. With Alastair’s expertise, the sky is the limit.”
Alastair Roriston , Director of Sales UK Public Sector, Pyramid Analytics:
“I am thrilled to have joined this innovative and ground-breaking company and even keener to assist in its expansion into the UK public sector. Throughout my career, I have seen the huge positive impact when the essential work of the public sector is married to the cutting-edge possibilities of technology – the opportunity for change is nearly limitless.
“I truly believe that Pyramid’s decision intelligence platform will revolutionise how government and public sector organisations deliver their digital and online services. Far too often, the wheels of public services are held up by siloed systems and antiquated approaches to data. A doctor should not have to wait precious minutes or hours for reports and patient data to arrive. Why should they not have that information and advice on next steps available in moments? Decision intelligence can eliminate these inefficiencies, making every frontline public sector worker a citizen data scientist with a world of dynamic, augmented analytics at their fingertips.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics.
1 GOV.UK
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005204/en/
Contact information
UK
Alex Izza
Resonance
+44 (0) 759 189 9654
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
